Laurence Fardet1, Irene Petersen, Irwin Nazareth. 1. MRC General Practice Research Framework, University College London Medical School, Stephenson House, 158-160 North Gower Street, London NW1 2ND, UK. laurence.fardet@sat.aphp.fr
Abstract
OBJECTIVE: To assess trends in long-term (i.e. ≥3 months) oral glucocorticoid (GC) prescriptions over the past 20 years. METHODS: Data of UK adult patients registered between January 1989 and December 2008 with general practices contributing to The Health Improvement Network (THIN) database were obtained. The annual prevalence of long-term oral GC prescriptions was assessed in the whole population and specifically in people with RA, PMR/GCA, asthma, chronic obstructive pulmonary disease (COPD), Crohn's disease and ulcerative colitis (UC). Trends over the 20-year period were estimated using sex- and age-adjusted Poisson regression models. RESULTS: During the 26 035 154 person-years of follow-up, an average of 0.75% (95% CI 0.74, 0.75) of the study population was prescribed long-term oral GC therapy at any time point. This rose from 0.59% (0.52, 0.67) in 1989 to 0.79% (0.78, 0.80) in 2008. Long-term prescriptions significantly increased in patients with RA [from 10.3% (8.7, 11.9) to 13.6% (12.9, 14.2)] and PMR/GCA [from 57.6% (53.3, 62.0) to 66.5% (65.2, 67.7)], decreased in patients with asthma, COPD and Crohn's disease and remained stable in patients with UC. However, when only incident cases were considered, we found a decreased use of GCs in patients with RA and UC [odds ratio 0.97 (95% CI 0.96, 0.97) and 0.94 (95% CI 0.93, 0.96) per increasing year, respectively]. CONCLUSION: Over the past 20 years, long-term oral GC prescriptions have increased by 34%. Patients newly diagnosed with RA, Crohn's disease or UC are, however, less likely to receive long-term GC prescriptions than patients with a long past medical history of the disease, suggesting changes in physicians' practice.
OBJECTIVE: To assess trends in long-term (i.e. ≥3 months) oral glucocorticoid (GC) prescriptions over the past 20 years. METHODS: Data of UK adult patients registered between January 1989 and December 2008 with general practices contributing to The Health Improvement Network (THIN) database were obtained. The annual prevalence of long-term oral GC prescriptions was assessed in the whole population and specifically in people with RA, PMR/GCA, asthma, chronic obstructive pulmonary disease (COPD), Crohn's disease and ulcerative colitis (UC). Trends over the 20-year period were estimated using sex- and age-adjusted Poisson regression models. RESULTS: During the 26 035 154 person-years of follow-up, an average of 0.75% (95% CI 0.74, 0.75) of the study population was prescribed long-term oral GC therapy at any time point. This rose from 0.59% (0.52, 0.67) in 1989 to 0.79% (0.78, 0.80) in 2008. Long-term prescriptions significantly increased in patients with RA [from 10.3% (8.7, 11.9) to 13.6% (12.9, 14.2)] and PMR/GCA [from 57.6% (53.3, 62.0) to 66.5% (65.2, 67.7)], decreased in patients with asthma, COPD and Crohn's disease and remained stable in patients with UC. However, when only incident cases were considered, we found a decreased use of GCs in patients with RA and UC [odds ratio 0.97 (95% CI 0.96, 0.97) and 0.94 (95% CI 0.93, 0.96) per increasing year, respectively]. CONCLUSION: Over the past 20 years, long-term oral GC prescriptions have increased by 34%. Patients newly diagnosed with RA, Crohn's disease or UC are, however, less likely to receive long-term GC prescriptions than patients with a long past medical history of the disease, suggesting changes in physicians' practice.
Authors: Gaurang C Patel; Tien N Phan; Prabhavathi Maddineni; Ramesh B Kasetti; J Cameron Millar; Abbot F Clark; Gulab S Zode Journal: Am J Pathol Date: 2017-02-04 Impact factor: 4.307
Authors: Serene Z Mirza; Jonathan T L Cheah; Nilasha Ghosh; Joanna C Robson; Catherine L Hill; Jasvinder Singh; Sarah L Mackie; Iris Navarro-Millán; Lee S Simon; Susan M Goodman Journal: J Clin Rheumatol Date: 2021-09-01 Impact factor: 3.517
Authors: SuJin Hwang; Christina Tatsi; Hye Sun Kuehn; Julie E Niemela; Jennifer Stoddard; Yan Su; Maya Lodish; Gulbu Uzel; Rosanne Spolski; Warren J Leonard; Steven M Holland; Thomas A Fleisher; Constantine A Stratakis; Sergio D Rosenzweig Journal: J Allergy Clin Immunol Date: 2021-06-02 Impact factor: 10.793